Caroline Seymour

1 week ago | onclive.com | Caroline Seymour

The addition of durvalumab (Imfinzi) to standard-of-care BCG induction and maintenance therapy led to a statistically significant and clinically meaningful improvement in disease-free survival (DFS) vs BCG induction and maintenance alone in patients with high-risk non–muscle-invasive bladder cancer (NMIBC), according to topline findings from the phase 3 POTOMAC trial (NCT03528694).1 A descriptive analysis also indicated no detriment in overall survival (OS) although the trial was not...

2 weeks ago | onclive.com | Caroline Seymour

Neoadjuvant therapy with the combination of botensilimab and balstilimab led to high response rates and a low rate of high-grade immune-related adverse effects (irAEs) in patients with solid tumors, according to data from the phase 2/3 pan-cancer NEOASIS trial (NCT06279130) presented at the 2025 AACR Annual Meeting.1During the safety run-in which evaluated 25 mg of botensilimab plus 450 mg of bastilimab, all 10 patients received both cycles of therapy.

2 weeks ago | onclive.com | Caroline Seymour

Transient γ9δ2 T-cell (γ9δ2TC) activation with a low dose of ICT01 (ICT01low) plus azacitidine and venetoclax (Venclexta; ICT01low-aza-ven) augmented responses without sacrificing tolerability in patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for standard intensive chemotherapy and hematopoietic stem cell transplant, according to data from the phase 1 ENVISION trial presented at the 2025 AACR Annual Meeting.1 Early onset and higher responses were seen with...

2 weeks ago | onclive.com | Caroline Seymour

Neoadjuvant therapy with dostarlimab-gxly (Jemperli) led to a clinical complete response (cCR) in 82% (95% CI, 72%-88%) of patients with early-stage mismatch repair–deficient (dMMR) solid tumors, according to updated data from a phase 2 study (NCT04165772) presented at the 2025 AACR Annual Meeting and subsequently published in the New England Journal of Medicine.1,2Of 49 patients with rectal cancer, all (100%) achieved a cCR at a median follow-up of 30.2 months.

2 weeks ago | onclive.com | Caroline Seymour

The presence of TMPRSS2-ERG fusions in circulating tumor DNA (ctDNA) was associated with differential gene alteration frequency, tumor mutational burden (TMB), and gene expression signatures, among other molecular characteristics in patients with metastatic castration-resistant prostate cancer (mCRPC), according to data from a post hoc analysis of the phase 3 TALAPRO-2 trial (NCT03395197) presented at the 2025 AACR Annual Meeting.1 The results demonstrated that ctDNA burden was higher in the...